The HDAC inhibitor Panobinostat has been approved by the FDA for the treatment of multiple myeloma, and the DNA methyltransferase inhibitor Decitabine for the treatment of myelodysplastic syndrome30, 31. Here, HDAC9 is linked to plasma cell myeloma.